This large international study confirms that atherothrombotic disease often occurs at more than one site. The ABI is related to the risk factor profile and to the site and extent of atherothrombosis.

No abstract

Despite recommendations issued in international and national guidelines, use of CAD medications in Asia remains suboptimal. In the absence of clear contraindications, all patients with unstable CAD should receive these agents as secondary prevention. This averts the need to target drug use according to risk, with high-risk features paradoxically associated with under-prescribing of such drugs.

Aims:Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Studies showing higher blood levels in Asians have resulted in concerns regarding increased adverse drug reactions. This study aimed to evaluate the efficacy and safety of rosuvastatin in hypercholesterolemic Asian patients. Methods: This retrospective observational study was conducted on statin-naive patients and statinswitch patients. Patients were treated with rosuvastatin for ≥ 8 weeks. Primary outcomes were changes in LDL-C levels and proportions of patients achieving their goals (primary prevention, LDL-C ≤ 130 mg/dL; secondary prevention, LDL-C ≤ 100 mg/dL). Results: Of 1007 hypercholesterolemic patients, 483 were statin-naive (LDL-C 161 40.8 mg/dL) and 524 were statin-switch patients (LDL-C 132.7 36.9 mg/dL). In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p 0.001). Eighty-one percent of these patients achieved LDL-C goals. In the statinswitch cohort, LDL-C, total cholesterol, and triglycerides levels were significantly reduced by 24.5%, 16.6%, and 3.8%, respectively (p 0.001). Achievement of target LDL-C levels increased from 29% to 72.9%. There was no significant adverse drug reaction. Conclusion